Werewolf Therapeutics (NASDAQ:HOWL) Director Luke Evnin Sells 33,948 Shares of Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 33,948 shares of the company’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $0.67, for a total transaction of $22,745.16. Following the sale, the director directly owned 1,239,060 shares in the company, valued at $830,170.20. This represents a 2.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Luke Evnin also recently made the following trade(s):

• On Tuesday, May 12th, Luke Evnin sold 67,885 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.64, for a total transaction of $43,446.40.
• On Friday, May 8th, Luke Evnin sold 305,741 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.70, for a total transaction of $214,018.70.
• On Thursday, May 7th, Luke Evnin sold 79,086 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.63, for a total transaction of $49,824.18.
• On Wednesday, May 6th, Luke Evnin sold 14,635 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.66, for a total transaction of $9,659.10.
• On Tuesday, May 5th, Luke Evnin sold 6,860 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.69, for a total transaction of $4,733.40.
• On Monday, May 4th, Luke Evnin sold 47,963 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.72, for a total transaction of $34,533.36.
• On Friday, May 1st, Luke Evnin sold 58,394 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.73, for a total transaction of $42,627.62.
• On Thursday, April 30th, Luke Evnin sold 168,262 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.72, for a total transaction of $121,148.64.
• On Wednesday, April 29th, Luke Evnin sold 56,559 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.69, for a total transaction of $39,025.71.
• On Tuesday, April 28th, Luke Evnin sold 95,412 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.73, for a total transaction of $69,650.76.

Werewolf Therapeutics Price Performance

HOWL opened at $0.63 on Wednesday. Werewolf Therapeutics, Inc. has a one year low of $0.53 and a one year high of $2.38. The company’s 50 day simple moving average is $0.81 and its 200-day simple moving average is $0.83. The stock has a market capitalization of $30.72 million, a P/E ratio of -0.51 and a beta of 0.41.

Werewolf Therapeutics (NASDAQ:HOWL) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.04. As a group, analysts anticipate that Werewolf Therapeutics, Inc. will post -1.29 EPS for the current year.

Analyst Ratings Changes

HOWL has been the topic of several research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Monday, April 20th. Wall Street Zen lowered shares of Werewolf Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Two analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $3.75.

Hedge Funds Weigh In On Werewolf Therapeutics

Several large investors have recently bought and sold shares of HOWL. Jane Street Group LLC acquired a new position in Werewolf Therapeutics in the second quarter valued at approximately $409,000. Renaissance Technologies LLC lifted its holdings in Werewolf Therapeutics by 48.6% in the fourth quarter. Renaissance Technologies LLC now owns 677,766 shares of the company’s stock valued at $429,000 after buying an additional 221,766 shares during the period. Citadel Advisors LLC acquired a new position in Werewolf Therapeutics in the third quarter valued at approximately $304,000. Vanguard Group Inc. lifted its holdings in Werewolf Therapeutics by 8.5% in the third quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock valued at $2,774,000 after buying an additional 109,796 shares during the period. Finally, Marshall Wace LLP acquired a new position in Werewolf Therapeutics in the second quarter valued at approximately $113,000. 64.84% of the stock is currently owned by institutional investors and hedge funds.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.